Please login to the form below

Not currently logged in
Email:
Password:

Stephen MacMillan resigns as Stryker’s chair, president and CEO

Curt Hartman takes over as interim CEO and William Parfet steps in as non-executive chairman at the US medical technology firm

Stephen MacMillan has resigned from his roles as chair, president and CEO of Stryker Corporation.

The US-based medical technology firm cited family reasons as the motivation for the departure of MacMillan, who had been chair for two years, CEO for seven years and president for nine years.

MacMillan said: "It has been an enormous privilege to have led Stryker during this period of important change and growth.

“As I look ahead to the next chapter in my life, I remain confident that the team will continue to execute Stryker's strategy with distinction and that the company will enjoy continued success in the future."

Replacing MacMillan as interim CEO is Stryker's current chief financial officer, Curt Hartman, while lead independent director William Parfet will take over as non-executive chairman.

Hartman, who has been with the company since 1990, has served as chief financial officer and vice president since 2009 and his previous roles include holding the post of global president of Stryker Instruments.

Parfet has been a director at Stryker for almost 20 years alongside his role as chair and CEO of drug safety and pharmaceutical development company MPI Research.

15th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics